Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
about
Patient-derived xenografts: a relevant preclinical model for drug developmentThe Role of ERK1/2 in the Development of Diabetic CardiomyopathyUsing Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer TherapyPrecision oncology based on omics data: The NCT Heidelberg experience.Of Mice and Melanoma: PDX System for Modeling Personalized Medicine.Patient-Derived Xenograft Models of Non-Small Cell Lung Cancer and Their Potential Utility in Personalized Medicine.MET/HGF pathway activation as a paradigm of resistance to targeted therapies.Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.Precision medicine driven by cancer systems biology.BRAF inhibitors amplify the pro-apoptotic activity of MEK inhibitors by inducing ER stress in NRAS-mutant melanoma.Melanoma central nervous system metastases: current approaches, challenges, and opportunities.Addressing intra-tumoral heterogeneity and therapy resistance.The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.Patient-derived tumor xenograft models for melanoma drug discovery.Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?MicroRNAs in melanoma development and resistance to target therapy.Cancer Chemoprevention by Phytochemicals: Nature's Healing Touch.Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma.Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma.Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.Double Trouble: Kinase domain duplication as a new path to drug resistance.Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenograftsRare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines.A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?Clinical Proteomics for Precision Medicine: The Bladder Cancer Case.PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.The Role of Resveratrol in Cancer Therapy.Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo.Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy.mTOR signaling-related MicroRNAs and Cancer involvement.
P2860
Q28067191-1BA90741-C65C-4098-B08E-0FF69A69AA8FQ28075539-638198FA-EF10-4230-9314-AD8263029D7DQ28076097-70D9297F-A304-447F-BED0-7D8345302D10Q36396606-6CC8F9FB-1C6B-4CAD-95C5-E724F8A79A88Q36759429-BAEA759D-CE9D-4F5F-9340-592056B4F3A0Q37592628-77DDACCA-7CA2-4A78-9710-799EE30595B0Q37597850-3CEF1B90-2277-41B0-A480-1662857856EFQ37632230-895F216F-F44C-4EEC-B4B8-1870ECA31BD7Q37742635-55E4FDF0-33D2-4B00-81F6-E00D7566521BQ38671474-4B22453E-2E50-45C9-A839-1EF3337A3A7DQ38807942-B2C0DA47-3830-48B7-B01E-18FFC098658DQ38823179-51A1C724-55FF-4DB7-8582-7F65793B741CQ38843111-910B2953-C46C-449C-9B5E-D25DE67641E2Q38907413-D405F5A8-B97F-41DD-9D84-C50D907FC680Q38917853-BE9C04B0-4682-496D-8996-3518C86ACDA5Q39101272-1D1387B8-839A-4877-8646-5D27EC2BFD52Q39168795-4F046401-299B-4ECC-BD41-11A0AD1E3319Q40091164-D23B2F6E-12DD-496A-9DEC-DA16B5F836E1Q41105052-A831D630-4716-4F91-BE5D-D32A5C2C889CQ41127791-07E32C74-ECB7-4CE3-A05A-F64F9E336200Q42332097-1908A241-F92E-4E27-A1D5-CDE48CE90A2CQ42344756-8145755A-146E-469F-BBD4-E9DE8B205DB8Q45347095-23FC74D4-3101-4D5C-B859-DE270207ABF4Q47107803-311927CD-7650-4063-814E-1429353DAC58Q47123308-91954ED1-8FEF-4A1C-809E-E0A730D7D992Q47573654-9D5618A4-876F-4F22-9102-5DF0B17CF97FQ47694209-3493EF0F-97A4-477B-B456-897627A34A74Q47736652-71A09867-A894-4FD0-B7A0-162F6CED9A78Q47940580-8218A740-D770-449B-A600-F5CA11579CA2Q50042449-1DE273AF-6963-4B55-9EC8-D9A3404BDEAFQ52591043-A987AEF5-5448-4929-8ED2-C26776F0AF1CQ52657766-ED1FD313-3A9E-432C-AD18-B38A9B06A4EDQ55069878-269E249F-55C1-47E8-B1C6-5B3ABBEA75D4
P2860
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Personalized Preclinical Trial ...... nd-Line Combination Therapies.
@ast
Personalized Preclinical Trial ...... nd-Line Combination Therapies.
@en
type
label
Personalized Preclinical Trial ...... nd-Line Combination Therapies.
@ast
Personalized Preclinical Trial ...... nd-Line Combination Therapies.
@en
prefLabel
Personalized Preclinical Trial ...... nd-Line Combination Therapies.
@ast
Personalized Preclinical Trial ...... nd-Line Combination Therapies.
@en
P2093
P2860
P50
P1476
Personalized Preclinical Trial ...... nd-Line Combination Therapies.
@en
P2093
Ashani T Weeraratna
Batool Shannan
Bradley Garman
Giordano Caponigro
Giorgos C Karakousis
Gordon B Mills
Katrin Sproesser
Lynn M Schuchter
Malte Peters
Marilda Beqiri
P2860
P304
P356
10.1158/1078-0432.CCR-15-1762
P407
P577
2015-12-16T00:00:00Z